<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Deliv</journal-id><journal-id journal-id-type="iso-abbrev">Drug Deliv</journal-id><journal-title-group><journal-title>Drug Delivery</journal-title></journal-title-group><issn pub-type="ppub">1071-7544</issn><issn pub-type="epub">1521-0464</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7906617</article-id><article-id pub-id-type="pmid">33620004</article-id><article-id pub-id-type="doi">10.1080/10717544.2021.1889720</article-id><article-id pub-id-type="publisher-id">1889720</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Nanophyto-gel against multi-drug resistant <italic>Pseudomonas aeruginosa</italic> burn wound infection</article-title><alt-title alt-title-type="left-running-head">M. M. Wen et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Ming Ming</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Abdelwahab</surname><given-names>Ibrahim A.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Aly</surname><given-names>Rania G.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>El-Zahaby</surname><given-names>Sally A.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutics &#x00026; Pharmaceutical Technology, Faculty of Pharmacy, Pharos University in Alexandria</institution>, <city>Alexandria</city>, <country>Egypt</country></aff><aff id="AF0002"><label>b</label><institution>Department of Microbiology and Immunology, Faculty of Pharmacy, Pharos University in Alexandria</institution>, <city>Alexandria</city>, <country>Egypt</country></aff><aff id="AF0003"><label>c</label><institution>Department of Pathology, Faculty of Medicine, Alexandria University</institution>, <city>Alexandria</city>, <country>Egypt</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Sally A. El-Zahaby <email>sally.elzahaby@yahoo.com</email><institution>Department of Pharmaceutics &#x00026; Pharmaceutical Technology, Faculty of Pharmacy, Pharos University in Alexandria</institution>, <city>Alexandria</city>, <country>Egypt</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>2</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>28</volume><issue>1</issue><fpage seq="41">463</fpage><lpage>477</lpage><permissions><copyright-statement>&#x000a9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IDRD_28_1889720.pdf"/><abstract><title>Abstract</title><p>Burn wound is usually associated by antibiotic-resistant <italic>Pseudomonas aeruginosa</italic> infection that worsens and complicates its management. An effective approach is to use natural antibiotics such as cinnamon oil as a powerful alternative. This study aims to investigate topical nanostructured lipid carrier (NLC) gel loaded cinnamon oil for <italic>Pseudomonas aeruginosa</italic> wound infection. A 2<sup>4</sup> full factorial design was performed to optimize the formulation with particle size 108.48&#x02009;&#x000b1;&#x02009;6.35&#x02009;nm, zeta potential &#x02212;37.36&#x02009;&#x000b1;&#x02009;4.01&#x02009;mV, and EE% 95.39&#x02009;&#x000b1;&#x02009;0.82%. FTIR analysis revealed no excipient interaction. Poloxamer 407 in a concentration 20% w/w NLC gel was prepared for topical application. Drug release exhibited an initial burst release in the first five hours, followed by a slow, sustained release of up to five days. NLC-cinnamon gel has a significant ability to control the drug release with the lowest minimum inhibitory concentration again <italic>P. aeruginosa</italic> compared to other formulations (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). <italic>In vivo</italic> study also showed NLC-cinnamon gel effectively healed the infected burned wound after a six-day treatment course with better antibacterial efficacy in burned animal models. Histological examination ensured the tolerability of NLC-cinnamon gel. The results suggest that nanoparticle-based cinnamon oil gel is a promising natural product against antibiotic-resistant strains of <italic>P. aeruginosa</italic> in wound infection.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Burn wounds</kwd><kwd>cinnamon oil</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd><kwd>nanostructured lipid carriers</kwd><kwd>nanophyto-gel</kwd><kwd>phytotherapy</kwd></kwd-group><counts><fig-count count="9"/><table-count count="7"/><page-count count="15"/><word-count count="8366"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Wound infection is the main risk factor in patients with burns, and burn wound caused by <italic>Pseudomonas aeruginosa</italic> is one of the most challenged wound care management in the hospitals (Jault et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">2018</xref>). Difficulties in management may arise from the severe inflammation of the tissues and untreated infections as well as the biofilms that might be formed as a result of microbial infection introducing more resistance to cure. Without proper treatment, an acute wound could develop into a chronic wound due to the presence of more virulent bacterial species which increases the mobility and economic burden of patients (Rahim et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">2017</xref>). Therefore, infection research is given as the top priority by the British Burns Association (BBA) for the patient benefit (The British Burns Association Research Special Interest Group, <xref rid="CIT0031" ref-type="bibr">2018</xref>).</p><p>There is a growing interest in the clinical use of natural products against antibiotic-resistant pathogens such as <italic>Pseudomonas aeruginosa</italic>, a biofilm-forming bacterium due to overuse of antibiotics. In this concern, more attention was given to include natural products in wound management seeking reduction of side effects encountered from too much consumption of chemicals, especially that the infected patients already had a special skin situation. One of these trending phyto-compounds is cinnamon bark oil which has been used in antimicrobial, antidiabetic, antioxidant, and anti-inflammatory applications with substantial beneficial evidence since ancient times. The active constituents of cinnamon oil are cinnamaldehyde (65&#x02013;80%) and eugenol (5&#x02013;10%) that have proven inhibition ability against <italic>P. aeruginosa</italic> to form antibiotic-resistant biofilms (Utchariyakiat et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2016</xref>). Another important feature of cinnamon oil is its ability to advance tissue regeneration and accelerate wound healing which will help wound patients in recovering their skin integrity (Seyed Ahmadi et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2019</xref>). However, low solubility and instability are the major limitation factors to achieve sustained delivery of this phyto-compound for clinical use (Bilia et&#x000a0;al., <xref rid="CIT0006" ref-type="bibr">2014</xref>). There were only a few published topical preparations aiming to deliver cinnamon oil in nanocarriers such as nano cream (Zainol et&#x000a0;al., <xref rid="CIT0038" ref-type="bibr">2015</xref>) and nanoemulsion (Mukerjee et&#x000a0;al., <xref rid="CIT0019" ref-type="bibr">2019</xref>) and yet none addressed wound infection. Thus, it is essential to design a cinnamon oil delivery system to overcome these challenges to maximize its therapeutic efficiency.</p><p>A nanostructured lipid carrier (NLC) is a colloidal, nanoparticle system that composes of a mixture of solid and liquid lipids and stabilized by surfactants in an aqueous phase for drug delivery. It can entrap a large number of lipophilic agents due to the imperfect matrix arisen from the mixed lipid components which prevent homogeneous crystal formation (Beloqui et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2016</xref>). NLCs are highly biodegradable and biocompatible and provide better drug delivery and skin permeation compared to solid lipid nanoparticles (Garc&#x000ea;s et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>). NLCs have been demonstrated in delivering highly lipophilic drugs into targeted organs, and damaged tissues such as burn wounds (Zahir-Jouzdani et&#x000a0;al., <xref rid="CIT0037" ref-type="bibr">2019</xref>). This study aims to investigate nanotechnology-based topical NLC-Cinnamon oil gel as a novel application for <italic>P. aeruginosa</italic> wound infection with better antibacterial efficacy <italic>in&#x000a0;vivo</italic>.</p></sec><sec sec-type="materials" id="S0002" disp-level="1"><label>2.</label><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Materials</title><p>Stearic acid was purchased from BDH Laboratory (Poole, UK). Tween 80 and Poloxamer 407 were from Sigma-Aldrich Co. (St. Louis, MO). Precirol<sup>&#x000ae;</sup> ATO 5 and Labrafac&#x02122; lipophile WL 1349 were kind gifts from Gattefosse (Lyon, France). All other chemicals used were of pharmaceutical grade.</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Extraction of <italic>Cinnamomum zeylanicum</italic> bark oil</title><p>The Clevenger hydrodistillation method (Pharmac Engineers, Mumbai, India) was used to extract freshly prepared essential oil (EO) from cinnamon bark of <italic>Cinnamomum zeylanicum</italic> imported from Oman. The dried bark 400&#x02009;g was first grounded into powder and transferred to a round bottom flask which was connected to the condenser and then boiled with one liter of distilled water for one hour and a half. The yield EO was dried over anhydrous sodium sulfate and stored in a dark glass bottle at 4&#x02013;8&#x02009;&#x000b0;C to prevent oxidative degradation. The final concentration used was 2.5&#x02009;mg/ml. The extracted oil was analyzed using GC/MS (Thermo Fisher Scientific, Dreieich, Germany) (data not shown). The major volatile oil constituents included cinnamaldehyde, cinnamic acid, cinnamyl acetate, and eugenol.</p></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Preparation of NSC-cinnamon oil</title><p>Two novel excipients Precirol ATO 5 and Labrafac&#x02122; lipophile WL 1349 were used to advance the formulation carrier. Labrafac is a mixture of medium-chain triglyceride and it is derived from vegetal origin and liquid at room temperature (Nanoscale, 2018). NSC-cinnamon oil was prepared according to the method described by Teng et&#x000a0;al. (<xref rid="CIT0030" ref-type="bibr">2019</xref>) with modification of temperature being 60&#x02009;&#x000b0;C for both lipid and aqueous phases which were then stirred vigorously with a high-speed homogenizer (IKA T25, Digital ULTRA TURRAX<sup>&#x000ae;</sup>, K&#x000f6;nigswinter, Germany) at 20,000&#x02009;rpm for 10&#x02009;min and followed by sonification in a water bath sonicator for 5&#x02009;min at 1500&#x000a0;W (Shyam Industries, Ahmedabad, India). The prepared NSCs were further continuously stirred at 100&#x02009;rpm overnight at room temperature. The formulation compositions were presented in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Compositions of NLC formulations.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Formula</th><th align="center">Precirol (mg)</th><th align="center">Stearic acid (mg)</th><th align="center">Labrafac (mg)</th><th align="center">Cinnamon oil (mg)</th><th align="center">Tween 80 (mg)</th><th align="center">Water (g)</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="char" char=".">833</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">8.7</td></tr><tr><td align="left">2</td><td align="char" char=".">1667</td><td align="char" char=".">0</td><td align="char" char=".">166</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">8</td></tr><tr><td align="left">3</td><td align="char" char=".">500</td><td align="char" char=".">0</td><td align="char" char=".">333</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">8.7</td></tr><tr><td align="left">4</td><td align="char" char=".">1667</td><td align="char" char=".">0</td><td align="char" char=".">166</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">7.7</td></tr><tr><td align="left">5</td><td align="char" char=".">500</td><td align="char" char=".">0</td><td align="char" char=".">333</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">9</td></tr><tr><td align="left">6</td><td align="char" char=".">1000</td><td align="char" char=".">0</td><td align="char" char=".">833</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">8</td></tr><tr><td align="left">7</td><td align="char" char=".">1000</td><td align="char" char=".">0</td><td align="char" char=".">833</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">7.7</td></tr><tr><td align="left">8</td><td align="char" char=".">833</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">9</td></tr><tr><td align="left">9</td><td align="char" char=".">0</td><td align="char" char=".">500</td><td align="char" char=".">333</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">8.7</td></tr><tr><td align="left">10</td><td align="char" char=".">0</td><td align="char" char=".">1667</td><td align="char" char=".">166</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">7.7</td></tr><tr><td align="left">11</td><td align="char" char=".">0</td><td align="char" char=".">1000</td><td align="char" char=".">833</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">8</td></tr><tr><td align="left">12</td><td align="char" char=".">0</td><td align="char" char=".">500</td><td align="char" char=".">333</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">9</td></tr><tr><td align="left">13</td><td align="char" char=".">0</td><td align="char" char=".">833</td><td align="char" char=".">0</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">8.7</td></tr><tr><td align="left">14</td><td align="char" char=".">0</td><td align="char" char=".">1000</td><td align="char" char=".">833</td><td align="char" char=".">167</td><td align="char" char=".">300</td><td align="char" char=".">7.7</td></tr><tr><td align="left">15</td><td align="char" char=".">0</td><td align="char" char=".">1667</td><td align="char" char=".">166</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">8</td></tr><tr><td align="left">16</td><td align="char" char=".">0</td><td align="char" char=".">833</td><td align="char" char=".">0</td><td align="char" char=".">167</td><td align="char" char=".">50</td><td align="char" char=".">9</td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>Factorial design for formulation optimization</title><p>A 2<sup>4</sup> full factorial experimental design was used to investigate the main effect and the interaction between these formulation factors. The experimental condition has four independent variables (A, B, C, and D) and two dependent variables (X1 and X2) that were set to select the optimum formula by a Design-Expert software (version 8.2, Stat-Ease Inc., Minneapolis, MN). The optimized formula should have the least particle size (PS) and the highest zeta potential (ZP) as an absolute value (<xref rid="t0002" ref-type="table">Table 2</xref>). Precirol ATO-5 and stearic acid were the tested solid lipids, while Labrafac and Tween 80 were the liquid lipid and surfactant, respectively. A total of 16 random runs were performed. Each run was performed in triplicate.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>2<sup>4</sup> full factorial design variables and levels of NLC-cinnamon oil.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Type of variables</th><th colspan="2" align="center">Levels</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">Factors (independent variables)</italic></td><td align="left">Lower limit</td><td align="left">Upper limit</td></tr><tr><td align="left">A: type of solid lipid</td><td align="left">Precirol</td><td align="left">Stearic acid</td></tr><tr><td align="left">B: ratio of solid to liquid lipid</td><td align="left">1:1 (min)</td><td align="left">5:1 (max)</td></tr><tr><td align="left">C: total lipids (%w/w)</td><td align="left">10 (min)</td><td align="left">20 (max)</td></tr><tr><td align="left">D: surfactant concentration (%w/w)</td><td align="left">0.5 (min)</td><td align="left">3 (max)</td></tr><tr><td align="left"><italic toggle="yes">Responses (dependent variables)</italic></td><td colspan="2">Desirability constraints</td></tr><tr><td align="left">X1: particle size (nm)</td><td colspan="2">Minimize</td></tr><tr><td align="left">X2: zeta potential (mV)</td><td colspan="2">Maximize (as an absolute value)</td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Physicochemical characterization of NLC</title><sec id="S0002-S2005-S3001" disp-level="3"><label>2.5.1.</label><title>Particle size, zeta potential, and polydispersity index measurement</title><p>Mean PS, ZP, and polydispersity index (PDI) of the formulations were determined by Zetasizer Nano ZS90 (Malvern Instruments Ltd., Malvern, UK) at 25&#x02009;&#x000b0;C at 90&#x000b0; angle. All samples were diluted with deionized water before analysis to reach a suitable scattering intensity. Each determination was performed in triplicates.</p></sec><sec id="S0002-S2005-S3002" disp-level="3"><label>2.5.2.</label><title>Transmission electron microscopy (TEM)</title><p>Envisioning of the nanoparticle shape and surface characteristics of the prepared NLCs were performed using TEM (Joel JEM 1230, Tokyo, Japan). The diluted dispersion is negatively stained using a saturated solution of uranyl acetate for 5&#x02009;min, followed by loading the stained formulation on a copper grid. A drying step of the copper grid lasted for 10&#x02009;min at 25&#x02009;&#x000b0;C followed by examination under the transmission electron microscope.</p></sec><sec id="S0002-S2005-S3003" disp-level="3"><label>2.5.3.</label><title>Fourier transform infrared (FT-IR) spectroscopy</title><p>Functional groups of the pure cinnamon oil, stearic acid, Labrafac, Tween 80, and the optimized formulation were analyzed in the range of 4000&#x02013;450&#x02009;cm<sup>&#x02212;1</sup> by Cary 630 FTIR Spectrometer (Agilent, Santa Clara, CA), set on 74 scans at 4&#x02009;cm<sup>&#x02212;1</sup> for each spectrum. All samples were analyzed with their original forms without further treatment.</p></sec><sec id="S0002-S2005-S3004" disp-level="3"><label>2.5.4.</label><title>Entrapment efficiency and drug loading (DL%)</title><p>The entrapment efficiency (EE%) of the cinnamon oil in NLC was determined indirectly by measuring the concentration of free cinnamon oil in the NLC-cinnamon oil colloid using a Spin-pure filter (MWCO 10&#x02009;kDa, Sera Care, Portland, ME). Accurately measured 100&#x000a0;&#x000b5;l NLC was diluted with 400&#x000a0;&#x000b5;l distilled water to remove unentrapped drugs that were deposited on the NLC surface. A total of 500&#x000a0;&#x000b5;l of this diluted sample mixture was transferred to the upper chamber of the filter tube which was then placed in a rotor and spun under ultracentrifugation at 20,000&#x02009;rpm for 45&#x02009;min at 4&#x02009;&#x000b0;C. The filtrate collected in the bottom chamber was analyzed by UV-VIS spectrophotometry (Shimadzu UV-1800, Kyoto, Japan) to determine the unentrapped drug concentration. The detection wavelength was 293&#x02009;nm. The EE% was calculated using the following equation. EE (%)&#x02009;=&#x02009;(total amount of drug in NLC&#x000a0;&#x02013;&#x000a0;free drug/total amount of drug in NLC)&#x02009;&#x000d7;&#x02009;100. All measurements were performed in triplicate.</p></sec></sec><sec id="S0002-S2006" disp-level="2"><label>2.6.</label><title>NLC-cinnamon oil gel</title><sec id="S0002-S2006-S3001" disp-level="3"><label>2.6.1.</label><title>Preparation of NLC-cinnamon oil gel</title><p>NLC-cinnamon oil gel was prepared by a &#x02018;cold&#x02019; method using thermosensitive Poloxamer 407 as a gelling agent (Wen et&#x000a0;al., <xref rid="CIT0035" ref-type="bibr">2012</xref>). A concentration of 20% w/w NLC gel was selected according to a preliminary study of the gel concentration and desired formulation viscosity (data not shown). To prepare 20% w/w control and formulation gels, 10&#x02009;g of Poloxamer 407 was dispersed in 50&#x02009;g deionized water or NLC colloid and mechanical, slowly stirred at 100&#x02009;rpm for two&#x000a0;hours at room temperature until a homogeneous dispersion was obtained. The mixture was stored in the refrigerator at 4&#x02009;&#x000b0;C for 24&#x02009;hours to ensure complete dissolution due to its characteristic gelation phenomenon which is dependent on the sol&#x02013;gel transition temperature (Tsol&#x02013;gel). Below Tsol&#x02013;gel, Poloxamer 407 aqueous solution is in solution form and turns into gel above this temperature (Dumortier et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2006</xref>).</p></sec><sec id="S0002-S2006-S3002" disp-level="3"><label>2.6.2.</label><title>Spreadability</title><p>The spreadability test was determined using the same method reported by Ibrahim et&#x000a0;al. (<xref rid="CIT0014" ref-type="bibr">2019</xref>). A glass slide was first marked with a 1&#x02009;cm diameter circle. Then, 0.1&#x02009;g of the tested gel was transferred to the center of the circle and covered with another glass slide. This sandwiched glass piece was warmed on a hot surface with a temperature of 32&#x02009;&#x000b1;&#x02009;0.84&#x02009;&#x000b0;C. A metal balance weight (500&#x02009;g) was topped over the glass cover for 5&#x02009;min. The expanded circle diameter was recorded. The spreadability of the gel was determined by the difference in the diameters of circles due to the spreading of the gel. All measurements were performed in triplicate.</p></sec><sec id="S0002-S2006-S3003" disp-level="3"><label>2.6.3.</label><title>pH measurement</title><p>The pH of the pure gel, blank NLC gel, and NLC-cinnamon oil gel was measured using a digital glass electrode-based pH meter (Schott Ger&#x000e4;te, Mainz, Germany) standardized using pH 4 and pH 7 buffers before use. Each sample (0.5&#x02009;g) was diluted with deionized water and dispersed uniformly before the measurement. In each measurement, the electrode was immersed into the sample for 10&#x02009;min to reach a steady reading. The experiments were performed in triplicate at room temperature.</p></sec><sec id="S0002-S2006-S3004" disp-level="3"><label>2.6.4.</label><title>Viscosity measurement</title><p>The apparent viscosities of the formulations were evaluated at 22.2&#x02009;&#x000b1;&#x02009;0.5&#x02009;&#x000b0;C using a Brookfield RV DV-II&#x02009;+&#x02009;pro viscometer equipped with a small sample adaptor. Each sample of 8&#x02009;ml was introduced carefully into the adaptor chamber to avoid entrapping air bubbles. The selected spindle (S15) was lowered into the sample and rotated at various speeds from 50 to 200&#x02009;rpm for at least 2&#x02009;min before each reading was taken. Viscosity was calculated as a mean value of three measurements in centipoise (cP).</p></sec></sec><sec id="S0002-S2007" disp-level="2"><label>2.7.</label><title><italic>In vitro</italic> drug release</title><p>The release study was carried out using a shaking incubator (WiseCube<sup>&#x000ae;</sup> WIS Precise Shaking Incubator, Wertheim, Germany) adjusted at 50&#x02009;rpm (35&#x02009;&#x000b1;&#x02009;0.5&#x02009;&#x000b0;C) for five days. Each formulation (2&#x02009;ml) was loaded into a dialysis membrane bag (MWCO 12&#x02013;14&#x02009;kDa, Spectra/por<sup>&#x000ae;</sup> Spectrum Laboratories Inc., Rancho Dominguez, CA) with both ends closed by a thread and hanged on a beaker containing 400&#x02009;ml release media of phosphate buffer pH 7.4 in which 30% absolute ethanol was added to ensure the sink condition for drug release. All membrane bags were immersed in the release media. The prepared beakers were positioned in the holders and gently shaken at a set speed in the incubator. One ml of released sample was withdrawn at the predetermined time intervals and replaced immediately by an equal volume of fresh, pre-warmed medium to maintain a constant receptor volume. Samples were suitably diluted and analyzed for the drug concentration by UV&#x02013;Vis spectrophotometry at a wavelength of 293&#x02009;nm. The amount of drug released was calculated according to the calibration curve equation (<italic>Y</italic>&#x02009;=&#x02009;0.087<italic>X</italic>&#x02009;+&#x02009;0.0234, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.9907). The dilution caused by the replenish media of each sample was corrected using a relevant equation. Triplicate data were collected and their means were plotted against time (Raafat &#x00026; El-Zahaby, <xref rid="CIT0023" ref-type="bibr">2020</xref>).</p></sec><sec id="S0002-S2008" disp-level="2"><label>2.8.</label><title>Determination of minimal inhibitory concentration (MIC)</title><p>The clinical isolates of <italic>P. aeruginosa</italic> strains were collected from burn and intensive care units in Alexandria University Main Hospital for this study and the patients were provided written informed consent. The isolation was approved by the ethical committee at the High Institute of Public Health, Alexandria University. Antimicrobial susceptibility testing was performed using the disc diffusion method, antibiotic discs tested were Meropenem (MEM, 10&#x02009;&#x003bc;g), Ampicillin/sulbactam (SAM, 10/10&#x02009;&#x003bc;g), Amoxicillin/Clavulanate (AMC, 10/10&#x02009;&#x003bc;g), Ciprofloxacin (CIP, 5&#x02009;&#x003bc;g), Cefepime (FEP, 30&#x02009;&#x003bc;g), Cefoperazone (CFP, 75&#x02009;&#x003bc;g), Cefotaxime (CTX, 30&#x02009;&#x003bc;g), Ceftriaxone (CRO, 30&#x02009;&#x003bc;g), Piperacillin (PIP, 100&#x02009;&#x003bc;g), Imipenem (IPM, 10&#x02009;&#x003bc;g), Gentamicin (CN, 10&#x02009;&#x003bc;g), Tetracycline (TE, 30&#x02009;&#x003bc;g), Levofloxacin (LEV, 5&#x02009;&#x003bc;g), Trimethoprim/Sulfamethoxazole (TMP/SMX, 1.25/23.75&#x02009;&#x003bc;g), Chloramphenicol (C, 30&#x02009;&#x003bc;g), Amikacin (AMK, 30&#x02009;&#x003bc;g), Aztreonam (ATM, 30&#x02009;&#x003bc;g), Ceftazidime (CAZ, 30&#x02009;&#x003bc;g) (Oxoid, Basingstoke, UK), and Colistin (CL, 10&#x02009;&#x003bc;g) (Himedia, Mumbai, India) to all isolates. Obtained values were interpreted according to the Clinical and Laboratory Standards Institute into sensitive, intermediate, and resistant categories.</p><p>The antibiotic susceptibility profile for all strains is shown in <xref rid="t0003" ref-type="table">Table 3</xref>. All <italic>P. aeruginosa</italic> isolates were resistant with varied resistance degrees for the tested antibiotics. The five isolated strains selected were multidrug-resistant and inoculated into the Luria-Bertani broth media with 30% glycerol and stored at &#x02212;80&#x02009;&#x000b0;C for later analysis.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Antibiogram of used multidrug resistant <italic>P. aeruginosa</italic> strains.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Organisms</th><th rowspan="2" align="center">No. of isolates</th><th colspan="19" align="center">The used antibiotics and percent of resistance pattern<hr/></th></tr><tr><th align="center">Gentamycin (GN)%</th><th align="center">Amikacin (AK)%</th><th align="center">Ampicillin/ Sulbactam (SAM)%</th><th align="center">Amoxicillin/ Clavulanate (AMC)%</th><th align="center">Cefepime (FEP)%</th><th align="center">Cefoperazone (CFP)%</th><th align="center">Cefotaxime (CTX)%</th><th align="center">Ceftriaxone (CRO)%</th><th align="center">Piperacillin (PIP)%</th><th align="center">Imipenem (IPM)%</th><th align="center">Meropenem (MEM)%</th><th align="center">Ciprofloxacin (CIP)%</th><th align="center">Levofloxacin (LEV)%</th><th align="center">Trimethoprim/ Sulfamethoxazole (SXT)%</th><th align="center">Aztreonam (ATM)%</th><th align="center">Ceftazidime (CAZ)%</th><th align="center">Chloramphenicol (C)%</th><th align="center">Colistin (CL)%</th><th align="center">Tetracycline (TE)%</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">P. aeruginosa</italic></td><td align="center">40</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">74.4</td><td align="center">74.4</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">100</td><td align="center">&#x02013;</td><td align="center">74.4</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">&#x02013;</td><td align="center">55.8</td><td align="center">74.4</td><td align="center">55.8</td><td align="center">55.8</td><td align="center">&#x02013;</td></tr></tbody></table></table-wrap><p>Broth microdilution method under standardized <italic>in&#x000a0;vitro</italic> conditions was used to measure the minimum inhibitory concentration (MIC) of the formulations using a 96-well microdilution tray (Grianer, Pleidelsheim, Germany) with twofold drug-dilution steps. The growth of bacteria was visually evaluated according to the clearness of the solution (Abozahra et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2020</xref>). The pure cinnamon oil, pure gel, NLC blank gel, NLC-cinnamon colloid, and NLC-cinnamon oil gel, 2.5&#x02009;mg/ml of each was twofold serially diluted with sterile nutrient broth, and then, 200&#x000a0;&#x000b5;l of each sample was transferred to the well of the microtiter tray. Ten &#x000b5;l of diluted broth cultures of <italic>Pseudomonas aeruginosa</italic> adjusted the bacterial suspension turbidity reaching a final inoculum of 0.5 McFarland turbidity standard which was transferred into each well. The microtiter tray was then incubated in the darkness at 37&#x02009;&#x000b0;C for 24&#x02009;hours, followed by visual inspection for bacterial growth by turbidity. Inoculated and uninoculated wells containing samples free of nutrient broth were used as controls to check the effect of the broth on the growth of the organism and the sterility. MIC value is the lowest concentration of each tested sample that inhibits the visible growth of <italic>P. aeruginosa</italic> (Jorgensen &#x00026; Ferraro, <xref rid="CIT0016" ref-type="bibr">2009</xref>; Limbago, <xref rid="CIT0018" ref-type="bibr">2019</xref>). These tests were performed in all five strains of clinical isolates.</p></sec><sec id="S0002-S2009" disp-level="2"><label>2.9.</label><title><italic>In vivo</italic> burnt wound study</title><p>Animal models used in the evaluation of the formulation treatment efficacy were male Sprague-Dawley rats (6&#x02013;8&#x000a0;weeks, 200&#x02013;220&#x02009;g) supplied by Animal Supply Unit, Pharos University in Alexandria, Alexandria, Egypt. The study protocol was approved by the Unit of Research Ethics on Animal Experimentation of Pharos University in Alexandria (file no. 3025/2019-10). Animal care in the facility complies with the &#x02018;Principles of Laboratory Animal Care&#x02019; by the American Society for Medical Research and the &#x02018;Guide for the Care and Use of Laboratory Animals&#x02019; by NIH (Bethesda, MD).</p><p>The animals were maintained under a standard laboratory-controlled environment with free access to food and water and kept in the same conditions for at least three days before the experiment. The hot water method was used to produce burn injury (Chang et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2020</xref>). A total of 15 rats were divided into five groups with three rats in each group. Group 1 received no treatment (negative control), group 2 received cinnamon oil dispersed in inert carrier olive oil, group 3 received NLC-cinnamon colloid, group 4 received NLC blank gel, and group 5 received NLC-cinnamon oil gel. The dorsal hairs of all rats were shaved by clipping and disinfected the shaved area with 70% alcohol one day before the experiment. Animals were weighed and anesthetized with ketamine and xylazine before the burning procedure. A rubber sheet with a 2&#x02009;cm circle opening was covered on the shaved dorsal skin. Rats were carried with the dorsal side down and immersed the exposed circular skin part into boiling water underneath for 10&#x02009;s to induce a third-degree burn (Selcuk et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2012</xref>). Thereafter, a suspension containing approximately 7.5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> colony forming units/ml (CFU/ml) <italic>P. aeruginosa</italic> was inoculated through an injection under the wound area. Animals were kept individually in separate cages and fed with a standard rat diet and water for two days before starting the treatment.</p><p>Each tested formulation containing 7&#x02009;mg of cinnamon oil was calculated for application amount in each group and applied onto the induced infected skin area of the rats once daily for six days. Bodyweight and burn edge contraction by the circle wound diameter were measured daily before the application of the next dose. Wound contraction was expressed as a reduction in the percentage of original wound diameter using the following equation (Tavares Pereira et&#x000a0;al., <xref rid="CIT0029" ref-type="bibr">2012</xref>):
<disp-formula id="M0001"><alternatives><graphic xlink:href="IDRD_A_1889720_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d2e906"><mml:mtext>Wound</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>contraction</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>on</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>day</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>X</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>%</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02009;=&#x02009;</mml:mo><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtext>area</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>on</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>day</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>area</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>on</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>day</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>X</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mtext>area</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>on</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>day</mml:mtext><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>&#x02009;&#x000d7;&#x02009;</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives></disp-formula>
</p><p>All animals were euthanized by cervical dislocation at the end of the treatment.</p></sec><sec id="S0002-S2010" disp-level="2"><label>2.10.</label><title>Histological examination</title><p>The experimental burn skin area of each rat was dissected immediately after sacrifice. The specimens of the cutaneous tissues including epidermis, dermis, and subcutaneous portions, from all groups, were fixed in 10% neutral-buffered formalin, dehydrated with an ascending ethanol gradient, cleared using xylol, and embedded in paraffin to form formalin-fixed, paraffin-embedded blocks (FFPE). The blocks were cut into 5&#x000a0;&#x000b5;m sections then stained with hematoxylin and eosin (H&#x00026;E). The sections were examined using different magnifications of the light microscope (Leica, Wetzlar, Germany) and photographed (Wen et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2014</xref>).</p></sec><sec id="S0002-S2011" disp-level="2"><label>2.11.</label><title>Statistical analysis</title><p>Design-Expert Program 8.2 software was used to generate a factorial design experiment and ANOVA was conducted to determine the significance of the factors and their interactions. For multiple comparisons, one-way analysis of variance (ANOVA) followed by post hoc Bonferroni&#x02019;s test when comparing all pairs or Dunnett&#x02019;s test when comparing pairs with control, with confidence degree 95% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05) (GraphPad Prism 7, La Jolla, CA). All data were expressed as the mean of three experiments&#x02009;&#x000b1;&#x02009;SD.</p></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Optimization of formulation by factorial design experiment</title><p>The formed NLC-cinnamon oil formulations were mostly white opaque colloids with various viscosities depending on the studied factors. Preliminary experimental trials were performed (data not shown) at first to select the factors as well as their levels. Full factorial design and statistical analysis were obtained using Design-Expert<sup>&#x000ae;</sup> software. The predicted <italic>R</italic><sup>2</sup> of 0.5279 for PS and 0.4882 for ZP is in reasonable agreement with the adjusted <italic>R</italic><sup>2</sup> of 0.6998 for PS and 0.6746 for ZP, respectively. This means both <italic>R</italic><sup>2</sup> values are rationally matched (Abd-Elsalam et&#x000a0;al., <xref rid="CIT0001" ref-type="bibr">2018</xref>). The factors and responses to the 16 random factorial runs are shown in <xref rid="t0004" ref-type="table">Table 4</xref>. The optimized formulation generated by the program with desirability 0.892 showed the following responses: 108.48&#x02009;&#x000b1;&#x02009;6.35&#x02009;nm of PS, &#x02212;37.36&#x02009;&#x000b1;&#x02009;4.01&#x02009;mV of ZP, solid:liquid lipid ratio of 4.5:1, total lipid concentration of 15.25% w/v, Tween 80 of 2.5% w/v, and stearic acid as solid lipid.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>The factorial design formulation matrix (<italic>n</italic>&#x02009;=&#x02009;3).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Random run</th><th align="center">Factor 1 (A)<break/>Types of solid lipid</th><th align="center">Factor 2 (B)<break/>Solid:liquid lipid ratio</th><th align="center">Factor 3 (C)<break/>Total lipid concentration % w/v</th><th align="center">Factor 4 (D)<break/>Surfactant concentration % w/v</th><th align="center">Response 1 (X1)<break/>Particle size, nm</th><th align="center">Response 2 (X2)<break/>Zeta potential, mV</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="left">Stearic acid</td><td align="center">5:1</td><td align="char" char=".">10.00</td><td align="char" char=".">3.00</td><td align="char" char=".">120.00&#x02009;&#x000b1;&#x02009;3.522</td><td align="char" char=".">&#x02212;37.60&#x02009;&#x000b1;&#x02009;3.66</td></tr><tr><td align="left">2</td><td align="left">Precirol</td><td align="center">1:1</td><td align="char" char=".">10.00</td><td align="char" char=".">0.50</td><td align="char" char=".">212.70&#x02009;&#x000b1;&#x02009;12.08</td><td align="char" char=".">&#x02212;25.20&#x02009;&#x000b1;&#x02009;2.71</td></tr><tr><td align="left">3</td><td align="left">Precirol</td><td align="center">5:1</td><td align="char" char=".">10.00</td><td align="char" char=".">3.00</td><td align="char" char=".">677.10&#x02009;&#x000b1;&#x02009;80.86</td><td align="char" char=".">&#x02212;38.70&#x02009;&#x000b1;&#x02009;6.33</td></tr><tr><td align="left">4</td><td align="left">Stearic acid</td><td align="center">5:1</td><td align="char" char=".">10.00</td><td align="char" char=".">0.50</td><td align="char" char=".">130.30&#x02009;&#x000b1;&#x02009;4.996</td><td align="char" char=".">&#x02212;34.70&#x02009;&#x000b1;&#x02009;3.38</td></tr><tr><td align="left">5</td><td align="left">Stearic acid</td><td align="center">1:1</td><td align="char" char=".">20.00</td><td align="char" char=".">0.50</td><td align="char" char=".">173.60&#x02009;&#x000b1;&#x02009;8.795</td><td align="char" char=".">&#x02212;39.00&#x02009;&#x000b1;&#x02009;4.02</td></tr><tr><td align="left">6</td><td align="left">Stearic acid</td><td align="center">1:1</td><td align="char" char=".">20.00</td><td align="char" char=".">0.50</td><td align="char" char=".">104.70&#x02009;&#x000b1;&#x02009;3.584</td><td align="char" char=".">&#x02212;30.80&#x02009;&#x000b1;&#x02009;4.31</td></tr><tr><td align="left">7</td><td align="left">Precirol</td><td align="center">1:1</td><td align="char" char=".">10.00</td><td align="char" char=".">3.00</td><td align="char" char=".">169.50&#x02009;&#x000b1;&#x02009;1.041</td><td align="char" char=".">&#x02212;39.10&#x02009;&#x000b1;&#x02009;6.00</td></tr><tr><td align="left">8</td><td align="left">Stearic acid</td><td align="center">5:1</td><td align="char" char=".">10.00</td><td align="char" char=".">3.00</td><td align="char" char=".">140.50&#x02009;&#x000b1;&#x02009;0.473</td><td align="char" char=".">&#x02212;35.60&#x02009;&#x000b1;&#x02009;3.24</td></tr><tr><td align="left">9</td><td align="left">Precirol</td><td align="center">1:1</td><td align="char" char=".">20.00</td><td align="char" char=".">0.50</td><td align="char" char=".">220.50&#x02009;&#x000b1;&#x02009;3.635</td><td align="char" char=".">&#x02212;35.20&#x02009;&#x000b1;&#x02009;5.12</td></tr><tr><td align="left">10</td><td align="left">Stearic acid</td><td align="center">5:1</td><td align="char" char=".">20.00</td><td align="char" char=".">3.00</td><td align="char" char=".">109.70&#x02009;&#x000b1;&#x02009;1.250</td><td align="char" char=".">&#x02212;43.10&#x02009;&#x000b1;&#x02009;7.06</td></tr><tr><td align="left">11</td><td align="left">Precirol</td><td align="center">5:1</td><td align="char" char=".">20.00</td><td align="char" char=".">0.50</td><td align="char" char=".">157.20&#x02009;&#x000b1;&#x02009;5.36</td><td align="char" char=".">&#x02212;23.80&#x02009;&#x000b1;&#x02009;1.96</td></tr><tr><td align="left">12</td><td align="left">Precirol</td><td align="center">1:1</td><td align="char" char=".">20.00</td><td align="char" char=".">3.00</td><td align="char" char=".">236.00&#x02009;&#x000b1;&#x02009;1.803</td><td align="char" char=".">&#x02212;34.60&#x02009;&#x000b1;&#x02009;2.68</td></tr><tr><td align="left">13</td><td align="left">Precirol</td><td align="center">5:1</td><td align="char" char=".">20.00</td><td align="char" char=".">0.50</td><td align="char" char=".">141.50&#x02009;&#x000b1;&#x02009;2.650</td><td align="char" char=".">&#x02212;11.30&#x02009;&#x000b1;&#x02009;3.99</td></tr><tr><td align="left">14</td><td align="left">Stearic acid</td><td align="center">1:1</td><td align="char" char=".">10.00</td><td align="char" char=".">0.50</td><td align="char" char=".">172.30&#x02009;&#x000b1;&#x02009;2.804</td><td align="char" char=".">&#x02212;43.50&#x02009;&#x000b1;&#x02009;6.39</td></tr><tr><td align="left">15</td><td align="left">Precirol</td><td align="center">3:1</td><td align="char" char=".">15.00</td><td align="char" char=".">3.00</td><td align="char" char=".">136.50&#x02009;&#x000b1;&#x02009;0.101</td><td align="char" char=".">&#x02212;35.50&#x02009;&#x000b1;&#x02009;3.87</td></tr><tr><td align="left">16</td><td align="left">Stearic acid</td><td align="center">5:1</td><td align="char" char=".">20.00</td><td align="char" char=".">3.00</td><td align="char" char=".">113.60&#x02009;&#x000b1;&#x02009;1.589</td><td align="char" char=".">&#x02212;30.30&#x02009;&#x000b1;&#x02009;2.07</td></tr></tbody></table></table-wrap><sec id="S0003-S2001-S3001" disp-level="3"><label>3.1.1.</label><title>Effect of formulation variables on particle size</title><p>Optimizing the PS of the topically applied NLC is one of the important factors to be considered during formulation development. A nano-sized system can increase the probability of better and deeper drug penetration into skin strata (Abd-Elsalam et&#x000a0;al., <xref rid="CIT0001" ref-type="bibr">2018</xref>). The effect of the formulation variables studied in the current research, including the type of solid lipid (A), solid:liquid lipid ratio (B), total lipid content (C), and surfactant concentration (D) on the mean NLC PS are illustrated in <xref ref-type="fig" rid="F0001">Figure 1</xref>. Stearic acid generated NLC with smaller PS than Precirol. The ANOVA data obtained from Design-Expert<sup>&#x000ae;</sup> software for NLC PS statistical analysis showed that type of solid lipid (A) had a significant effect on the mean PS with stearic acid better than Precirol<sup>&#x000ae;</sup> in decreasing the PS (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). Compared to Precirol<sup>&#x000ae;</sup>, stearic acid has a much shorter carbon chain length which may permit the accommodation of a greater amount of active ingredient due to more space availability as suggested by Mahant et&#x000a0;al. (<xref rid="CIT0025" ref-type="bibr">2018</xref>). On the other hand, solid:liquid lipid ratios also showed a significant effect on NLC mean PS (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05), where the smallest PS was found in the 1:1 ratio. This result was in agreement with a study reported by Sathe et&#x000a0;al. (<xref rid="CIT0026" ref-type="bibr">2019</xref>) where the PS of NLC prepared using solid lipid (Precirol<sup>&#x000ae;</sup> ATO 5) and liquid lipid Labrafac<sup>TM</sup> PG had decreased from 321.06&#x02009;&#x000b1;&#x02009;7.73&#x02009;nm to 280&#x02009;&#x000b1;&#x02009;15.583&#x02009;nm when they used ratios of 2:1 and 1:1, respectively. Furthermore, a significant effect of total lipid concentration on NLC PS was also found (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). PS decreased upon increasing the total lipid concentration from 10 to 20%. Higher lipid amount leads to the higher viscosity of NLC surface in which Labrafac<sup>TM</sup> may tend to cause immense disorder in the crystal lattice due to its high HLB of 10, resulting in spontaneous emulsification in the presence of surfactant and yielding smaller PS. Our results came in agreement with those found by Gaba et&#x000a0;al. (<xref rid="CIT0012" ref-type="bibr">2015</xref>), where the PS decreased when they increased the concentration of total lipid in their NLC system. One has to consider the interactions between all factors and the materials used in the formulation. The PS of the formed NLC in this study decreased when surfactants concentration increased from 0.5 to 3%. It is also reported that NLC of lower PS can be obtained using high surfactant concentration (Pardeike et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2011</xref>). Higher surfactant concentration means reduced surface tension and consequently smaller size particles can be formed (Uprit et&#x000a0;al., <xref rid="CIT0032" ref-type="bibr">2013</xref>). Overall, total lipid and surfactant concentrations had more profound effects on the PS reduction.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>3D plot model graphs demonstrating the effect of factors. (A) Type of solid lipid, (B) solid:liquid lipid ratio, (C) total lipid content, and (D) SAA concentration on mean particle size (nm).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0001_C"/></fig></sec><sec id="S0003-S2001-S3002" disp-level="3"><label>3.1.2.</label><title>Effect of formulation variables on zeta potential</title><p><xref ref-type="fig" rid="F0002">Figure 2</xref> shows the effect of factors; A: type of solid lipid, B: solid:liquid lipid ratio, C: total lipid content, and D: SAA concentration on mean ZP (mV). The model generated for the ZP graphs had a <italic>p</italic> value of &#x02009;&#x0003c;&#x02009;.0001 and an <italic>F</italic>-value of 7.43 which implied the significance of the model. The predicted <italic>R</italic><sup>2</sup> of 0.4882 is in reasonable agreement with the adjusted <italic>R</italic><sup>2</sup> of 0.6746. The ZPs of all the prepared NLCs were negative and ranged from &#x02212;11.30&#x02009;&#x000b1;&#x02009;3.99 to &#x02212;43.10&#x02009;&#x000b1;&#x02009;7.06&#x02009;mV. The negative charge is attributed to the presence of either stearic acid or Precirol. Most of the NLCs had ZP values high enough to ensure physical stability due to both electrostatic repulsions and steric hindrance in the presence of long chains in the SAA structure (Vasanth et&#x000a0;al., <xref rid="CIT0034" ref-type="bibr">2020</xref>). Besides, the PDI of these formulations ranged from 0.181 to 0.548 indicating homogeneity of nanoparticle size distribution.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>3D plot model graphs demonstrating the effect of factors. (A) Type of solid lipid, (B) solid:liquid lipid ratio, (C) total lipid content, and (D) SAA concentration on mean zeta potential (mV).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0002_C"/></fig></sec></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Transmission electron microscopy</title><p>TEM image confirmed that the prepared formulation contains smooth-surfaced spherical nanoparticles with an average size of 99.99&#x02009;nm and uniform size distribution of the formed nanoparticles (<xref ref-type="fig" rid="F0003">Figure 3</xref>).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>TEM image of NLC-cinnamon oil formulation.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0003_C"/></fig></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>Fourier transform infrared spectroscopy</title><p>FTIR analysis based on molecular vibrations of band spectra is presented in <xref ref-type="fig" rid="F0004">Figure 4</xref>. The purity of the cinnamon oil from the prepared extract was confirmed with the theoretical frequency of the band (Boughendjioua et&#x000a0;al., <xref rid="CIT0007" ref-type="bibr">2017</xref>) which showed the characteristic absorption peaks of the functional groups in chemical composition with aldehyde C=O stretching at 1743 and 1681&#x02009;cm<sup>&#x02212;1</sup> and the strongest IR absorptions of carbonyl stretching at 1626&#x02009;cm<sup>&#x02212;1</sup>. These peaks corresponded to high levels of cinnamaldehyde and aldehydes of the sample. There was also the presence of unsaturated C=C stretching at 1576 and 1451&#x02009;cm<sup>&#x02212;1</sup> and the aromatic =C&#x02013;H stretching peak at 3008&#x02009;cm<sup>&#x02212;1</sup> which was slightly higher than the &#x02013;C&#x02013;H stretching in alkanes at 2926&#x02009;cm<sup>&#x02212;1</sup>. Compared with pure cinnamon oil, the disappearance of these characteristic absorptions in the bands of spectrum of NLC-cinnamon oil indicated that cinnamon oil is well entrapped inside the nanocarriers. Also, the characteristic C&#x02013;H asymmetric stretching peak of stearic acid at 2914&#x02009;cm<sup>&#x02212;1</sup> and C&#x02013;H symmetric stretching at absorbance peak at 2840&#x02009;cm<sup>&#x02212;1</sup> (Amanda Velinna Fernandes et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2020</xref>) became much weaker in the absorption bands of NLC-cinnamon oil, indicating that stearic acid was well incorporated into nanoparticles. The broad O&#x02013;H band around 3364&#x02013;3229&#x02009;cm<sup>&#x02212;1</sup> in NLC-cinnamon oil became shorter because the formulation was stabilized by Tween 80. The nanoformulation also showed hydrogen bond in hydrocarbon chain with bands at 2964 and 2844&#x02009;cm<sup>&#x02212;1</sup> and carbonyl group at 1733 and 1675&#x02009;cm<sup>&#x02212;1</sup>. C=C stretch was also observed at 1541 and 1471&#x02009;cm<sup>&#x02212;1</sup>. Overall, the IR chart indicated a good formation of NLC nanoformulation which efficiently entrapped cinnamon oil with no excipient interaction.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>FTIR band spectra of cinnamon oil, stearic acid, Labrafac, Tween 80, and the chosen NLC-optimized formulation.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0004_C"/></fig></sec><sec id="S0003-S2004" disp-level="2"><label>3.4.</label><title>Entrapment efficiency</title><p>Entrapment efficiency is one of the important parameters in developing nanoparticle delivery systems. High EE% indicates that the drug is successfully entrapped into the nanoparticle (Zhang et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2013</xref>). Cinnamon oil was very well entrapped in the nanoparticles with a high EE% of 95.39&#x02009;&#x000b1;&#x02009;0.82% which confirmed the suitability and effectiveness of formulation design using NLC as nanocarriers for cinnamon oil.</p></sec><sec id="S0003-S2005" disp-level="2"><label>3.5.</label><title>Spreadability, pH, and viscosity of the NLC gel</title><p>Poloxamer 407 is a hydrophilic, nonionic copolymer with a center block of hydrophobic polypropylene oxide (PPO) and two hydrophilic polyethylene oxide (PEO) blocks on both sides. This thermosensitive hydrogel has bioadhesive properties and many applications in drug delivery showing the controllable sustained release of the drug from the formulation, such as parenteral, ophthalmic, nasal, vaginal, rectal, and topical applications (Fakhari et&#x000a0;al., <xref rid="CIT0011" ref-type="bibr">2017</xref>). In preparation, Poloxamer 407 aqueous dispersion remains liquid under Tsol-gel due to self-assemble into micelles. Upon increasing the temperature, the polymer starts the gelling process due to the dehydration of the hydrophobic PPO blocks (Denisa Ficai, <xref rid="CIT0009" ref-type="bibr">2017</xref>).</p><p>The prepared NLC-cinnamon oil gel is a soft gel with milky color and pH 6.30&#x02009;&#x000b1;&#x02009;1.02 which is suitable for topical application. <xref rid="t0005" ref-type="table">Table 5</xref> shows the comparison of spreadability and viscosity of the selected formulation and the control gels which exhibits a negative relation between the spreadability and viscosity. The lipid contents in the NLC increased the gel&#x02019;s apparent viscosity. The viscosity of NLC-cinnamon oil gel was increased to 977.26&#x02009;&#x000b1;&#x02009;22.6&#x000a0;cP which is about double the viscosity of the pure Poloxamer 407gel of 445.38&#x02009;&#x000b1;&#x02009;28.89&#x000a0;cP.</p><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Comparison of the spreadability and viscosity of pure gel, blank NLC gel, and NLC-cinnamon oil gel (values are expressed as mean &#x000b1; 1 SD, <italic>n</italic>&#x02009;=&#x02009;3).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="center">Spreadability diameter (cm)</th><th align="center">Viscosity (cP) (150&#x02009;rpm, 22.2&#x02009;&#x000b1;&#x02009;0.5&#x02009;&#x000b0;C)</th></tr></thead><tbody valign="top"><tr><td align="left">Pure gel</td><td align="char" char="&#x000b1;">2.53&#x02009;&#x000b1;&#x02009;0.59</td><td align="char" char="&#x000b1;">445.38&#x02009;&#x000b1;&#x02009;28.89</td></tr><tr><td align="left">Blank NLC gel</td><td align="char" char="&#x000b1;">1.82&#x02009;&#x000b1;&#x02009;0.31</td><td align="char" char="&#x000b1;">689.86&#x02009;&#x000b1;&#x02009;49.47</td></tr><tr><td align="left">NLC-cinnamon oil gel</td><td align="char" char="&#x000b1;">1.46&#x02009;&#x000b1;&#x02009;0.23</td><td align="char" char="&#x000b1;">977.26&#x02009;&#x000b1;&#x02009;54.24</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2006" disp-level="2"><label>3.6.</label><title><italic>In vitro</italic> drug release</title><p>The percent cumulative cinnamon oil released from both NLC gel and colloidal systems were compared to the gel containing only the pure cinnamon oil. The drug release profile exhibited an initial burst release in all tested formulations in the first five hours, followed by a slow, sustained release up to five days; however, the NLC-cinnamon oil gel has less burst release effect compared to the NLC-cinnamon oil colloid and cinnamon oil gel, indicating gel containing NLC effectively entrapped cinnamon oil and controlled its release from the formulation (<xref ref-type="fig" rid="F0005">Figure 5</xref>). Herein, more control of the drug release was observed in the case of NLC-cinnamon oil gel in which the release pattern of cinnamon oil has achieved sustained manner. This result strongly confirmed an additive contributing effect of both NLC nanoparticles and gel base as barriers to the release of entrapped cinnamon oil. The difference calculated for NLC-cinnamon gel and cinnamon oil gel was found to be 45.84, indicating that the curves were not similar. Moreover, one-way ANOVA showed significant difference between the releases of cinnamon oil from these tested formulations. Further, post hoc Tukey&#x02019;s multiple comparison tests found significant differences in drug release between the NLC-cinnamon oil gel and NLC-cinnamon colloid, and NLC-cinnamon oil gel and cinnamon oil gel (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05); however, no significant difference found in drug release between the NLC-colloid and cinnamon oil gel (<italic>p</italic>&#x0003e;.05) which further implied the synergistic effect in retarding the drug release.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p><italic>In vitro</italic> release of cinnamon oil from NLC colloid and gel compared to pure cinnamon oil gel in phosphate buffer pH 7.4 containing 30% absolute ethanol at 35&#x02009;&#x000b1;&#x02009;0.5&#x02009;&#x000b0;C (<italic>n</italic>&#x02009;=&#x02009;3).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0005_C"/></fig><p>By the 5th day, 51.6% of cinnamon oil was released from the NLC gel compared to 63.1% from the NLC colloid and 63.7% from the gel. To further explain this result, based on Fick&#x02019;s law of diffusion and the Noyes&#x02013;Whitney equation theories, experimental data were appropriately fitted into the Nernst&#x02013;Brunner equation d<italic>C</italic>/d<italic>t</italic>&#x02009;=&#x02009;<italic>DS</italic> (<italic>Cs</italic>&#x000a0;&#x02013;&#x000a0;<italic>C</italic>)/<italic>Vh</italic>, where, drug dissolution rate (d<italic>C</italic>/d<italic>t</italic>) is inversely proportional to path length (<italic>h</italic>). Herein, an increase in path length traversed by cinnamon oil through both NLC and gel until reaching the dissolution media will in turn decrease its release rate (Vasanth et&#x000a0;al., <xref rid="CIT0034" ref-type="bibr">2020</xref>). Furthermore, we investigated the release mechanism of cinnamon oil from different formulations using various mathematical models, including zero-order, first-order, Higuchi, and Korsmeyer&#x02013;Peppas models. The model with the highest coefficient of determination (<italic>R</italic><sup>2</sup>) was considered to be the best fitting one. Cinnamon oil released from all test samples was found to follow the Korsmeyer&#x02013;Peppas model (<xref rid="t0006" ref-type="table">Table 6</xref>), with a best fit <italic>R</italic><sup>2</sup> value of 0.976, and <italic>n</italic> is equal to 0.409, 0141, and 0.234 for NLC-gel, NLC-colloid, and cinnamon oil, respectively. All the tested samples have a Fickian diffusion mechanism of drug release.</p><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Modeling of drug release from NLC-cinnamon gel, NLC-cinnamon colloid, and cinnamon oil-gel formulations.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">&#x000a0;</th><th align="center">Zero-order</th><th align="center">First-order</th><th align="center">Higuchi</th><th colspan="2" align="center">Korsmeyer&#x02013;Peppas<hr/></th></tr><tr><th align="center"><italic toggle="yes">R</italic><sup>2</sup></th><th align="center"><italic toggle="yes">R</italic><sup>2</sup></th><th align="center"><italic toggle="yes">R</italic><sup>2</sup></th><th align="center"><italic toggle="yes">R</italic><sup>2</sup></th><th align="center"><italic toggle="yes">n</italic></th></tr></thead><tbody valign="top"><tr><td align="left">NLC-gel</td><td align="char" char=".">0.604</td><td align="char" char=".">0.758</td><td align="char" char=".">0.953</td><td align="char" char=".">0.976</td><td align="char" char=".">0.409</td></tr><tr><td align="left">NLC-colloid</td><td align="char" char=".">&#x02013;4.000</td><td align="char" char=".">&#x02013;1.298</td><td align="char" char=".">&#x02013;1.590</td><td align="char" char=".">0.760</td><td align="char" char=".">0.141</td></tr><tr><td align="left">Cinnamon oil-gel</td><td align="char" char=".">&#x02013;0.676</td><td align="char" char=".">&#x02013;0.022</td><td align="char" char=".">0.297</td><td align="char" char=".">0.794</td><td align="char" char=".">0.234</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2007" disp-level="2"><label>3.7.</label><title>Determination of minimal inhibitory concentration</title><p>Cinnamon bark oil has a wide variety of antimicrobial activities due to the presence of chemical compounds as cinnamaldehyde (the main constituent), eugenol, coumarin, and O-methoxycinnamaldehyde (Utchariyakiat et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2016</xref>). The antimicrobial effect of the cinnamon oil exerts probably through the action of these compounds. The concentration tested in this study were 0.0039%, 0.0078%, 0.0156%, 0.03125%, 0.0625%, 0.125%, 0.25%, and 0.5% w/v. <xref rid="t0007" ref-type="table">Table 7</xref> shows that NLC-cinnamon oil gel exhibits significant inhibitory activity against the test strain <italic>P. aeruginosa</italic> compared to all other formulations, with the lowest MIC of 312.50&#x02009;&#x003bc;g/ml (ANOVA, <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). NLC-cinnamon oil colloid also showed a stronger anti-microbial effect than the cinnamon oil alone which was in agreement with the finding by Kim et&#x000a0;al. (<xref rid="CIT0017" ref-type="bibr">2015</xref>) that showed marked inhibition of biofilm formation, swarming motility, and the hemolytic activity of <italic>P. aeruginosa</italic> by cinnamon bark oil. The enhanced anti-microbial activity in NLC-cinnamon oil gel may also contribute to nanoparticles with large surface area and the lipophilic nature of the NLCs which enable better bacterial cell penetration and uptake (Osman et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2019</xref>). Both NLC-cinnamon colloid and NLC-cinnamon gel showed statistically significant MIC again <italic>P. aeruginosa</italic> compared to the cinnamon oil group (post hoc Bonferroni&#x02019;s test, <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). The excipients of plain gel and NLC blank gel had no inhibitory effect against <italic>P. aeruginosa</italic> with the tested concentrations. The percentages decrease in MIC from NLC-cinnamon colloid and NLC-cinnamon gel compared to pure cinnamon oil was 75% and 87.5%, respectively.</p><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Comparison of MIC against five strains of <italic>P. aeruginosa</italic> in formulation and excipients.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="center">MIC (&#x000b5;g/ml) (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5)</th></tr></thead><tbody valign="top"><tr><td align="left">Cinnamon oil</td><td align="left">2250.00&#x02009;&#x000b1;&#x02009;559.02</td></tr><tr><td align="left">Plain gel</td><td align="left">N/A</td></tr><tr><td align="left">NLC blank gel</td><td align="left">N/A</td></tr><tr><td align="left">NLC-cinnamon oil colloid</td><td align="left">562.00&#x02009;&#x000b1;&#x02009;139.75</td></tr><tr><td align="left">NLC-cinnamon oil gel</td><td align="left">281.20&#x02009;&#x000b1;&#x02009;69.99</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2008" disp-level="2"><label>3.8.</label><title><italic>In vivo</italic> burnt wound study</title><p>Visual assessment of the wound surface and edge contraction daily (<xref ref-type="fig" rid="F0006">Figure 6</xref>) showed that group 3 has similar healing progress as group 5 in the appearance of skin structure regrowth; however, group 5 presented more completed induration of firmly new skin growth and smooth wound edge with no signs of infection. The infected wound in group 1 (no treatment) appeared persistent erythematous infectious lesion during the treatment period with no improvement. Skin lesion in group 2, on the other hand, showed edematous and scarred surface with diffused wound edge which may be due to the irritation effect of the diluted cinnamon oil in the carrier oil directly applied on the open wound.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Images of original burn wound (day 0) and after treatment on day 6. Group 1: no treatment, group 2: cinnamon oil, group 3: NLC-cinnamon oil colloid, group 4: NLC blank gel, and group 5: NLC-cinnamon oil gel.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0006_C"/></fig><p>The reduction of body weight during the treatment period was highest in group 1 of 1.8498&#x02009;g/day and lowest in group 5 of 0.7708&#x02009;g/d (<xref ref-type="fig" rid="F0007">Figure 7</xref>). The percentage of wound contraction on day 6 (%) after completion of the treatment was in the order of group 5 (100.00%), group 3 (97.22%), group 2 (75.00%), group 4 (55.55%), and group 1 (30.55%). Treatment of NLC-cinnamon oil gel successfully healed the wound in six days.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Weight changes during the treatment. Group 1: no treatment, group 2: cinnamon oil, group 3: NLC-cinnamon oil colloid, group 4: NLC blank gel, and group 5: NLC-cinnamon oil gel.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0007_C"/></fig><p>The effectiveness of the tested formulation was additionally compared with control and excipient formulations by measuring the burn area contraction of the wound healing mechanism in rats (Abdullahi et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2014</xref>). <xref ref-type="fig" rid="F0008">Figure 8</xref> shows that the burn contraction area was the smallest in group 5. Importantly, ANOVA (GraphPad Prism 8, La Jolla, CA) showed a significant difference between all groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.0001). Further post hoc with Bonferroni&#x02019;s pairwise comparisons indicated a significant reduction of burn contraction area between the control (group 1) and tested formulation (group 5) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01), achieving the antibacterial outcome and accelerated wound healing. The rate of reduction in burn wound area was also highest in group 5 with 1.787&#x02009;cm<sup>2</sup>/d and in the descending order of group 5 (1.787&#x02009;cm<sup>2</sup>/d), group 3 (1.665&#x02009;cm<sup>2</sup>/d), group 2 (1.2962&#x02009;cm<sup>2</sup>/d), group 4 (0.8572&#x02009;cm<sup>2</sup>/d), and group 1 (0.4548&#x02009;cm<sup>2</sup>/d). Overall, NLC-cinnamon oil gel achieved significant completed wound healing on the burn wound infected by <italic>P. aeruginosa</italic> after a six-day treatment course.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Burn area contraction (cm<sup>2</sup>) of tested groups. Group 1: no treatment, group 2: cinnamon oil, group 3: NLC-cinnamon oil colloid, group 4: NLC blank gel, and group 5: NLC-cinnamon oil gel (<italic>p</italic>&#x0003c;.0001).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0008_C"/></fig></sec><sec id="S0003-S2009" disp-level="2"><label>3.9.</label><title>Histological examination</title><p><xref ref-type="fig" rid="F0009">Figure 9</xref> shows that the skin specimen from the normal control group presented typical cellular integrity with an intact surface epithelium, normal dermis, and subcutaneous tissue lacking any inflammatory infiltrate. The skin specimens from group 1 (without any treatment) showed a third-degree burn with wide ulceration of the surface epithelium covered by fibroid inflammatory exudate. The dermis part contained an inflammatory infiltrate formed of mixed acute and chronic inflammatory cells of neutrophils, lymphocytes, plasma cells, and histiocytes. The second group treated with cinnamon oil gel showed a smaller skin ulcer, compared to the first group, covered by fibrinoid material. The dermis and subcutaneous tissue showed mixed acute and chronic inflammatory cells. Group 3 (NLC-cinnamon colloid) showed a wide area of granulation tissue and fibrosis denoting the healing process with minor inflammatory infiltrate. The fourth group (NLC blank gel) showed skin ulceration covered by the fibrinoid material. Area of granulation tissue and fibrosis appeared in the dermis and subcutaneous tissue; however, less than group 3, while the inflammatory infiltrates were more than that of group 3. The fifth group (NLC-cinnamon gel) showed the most remarkable amount of fibrosis of the dermis and subcutaneous tissue with only a few inflammatory cells toward completion of healing.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Rat skin samples after the six-day treatment. (A) The normal skin control group showed intact skin surface epithelium and normal dermal and subcutaneous tissues without inflammation (H&#x00026;E, &#x000d7;100). (B) Group 1 &#x02013; no treatment: wide ulceration of the surface (blue arrow) covered by an excessive amount of fibrinoid material (red arrow). The dermis and the subcutaneous tissue show mixed acute and chronic inflammatory cells (green arrow), H&#x00026;E &#x000d7;200. (C) Group 2 &#x02013; cinnamon oil gel: smaller skin ulcers (blue arrow) covered by fibrinoid material (red arrow). The dermis and subcutaneous tissue show inflammatory infiltrate (green arrow) and fibrosis (black arrow) H&#x00026;E &#x000d7;200. (D) Group 3 &#x02013; NLC-cinnamon oil colloid: wide areas of granulation tissue (green arrow) admixed with fibrosis denoting the healing process (black arrow) H&#x00026;E &#x000d7;200. (E) Group 4 &#x02013; NLC blank gel: focal ulcerated area covered by fibrinoid material (red arrow) with small areas of granulation tissue and fibrosis (black arrow) extending to the dermis and subcutaneous tissue with moderate mixed acute and chronic inflammatory infiltrate (green arrow), H&#x00026;E &#x000d7;200. (F) Group 5 &#x02013; NLC-cinnamon oil gel: wide areas of granulation tissue and fibrosis occupying the whole dermis (black arrow), H&#x00026;E &#x000d7;200.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1889720_F0009_C"/></fig></sec></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><label>4.</label><title>Conclusions</title><p>Treatment for infected wounds should not only inhibit the causing microorganism but also promote the wound healing repairing process. The infected wound in experimental rats revealed that NLC-cinnamon oil gel significantly improved wound contraction percentage compared to the untreated and cinnamon oil groups by accelerated wound healing and antimicrobial effect. Our findings suggest that topical administration of NLC-cinnamon oil gel resulted in a significant antimicrobial activity and promotion of wound healing and skin regeneration. The studied nanoparticle-based cinnamon oil gel is a promising natural product against antibiotic-resistant strains of <italic>Pseudomonas aeruginosa</italic> in wound infection.</p></sec></body><back><ack><title>Acknowledgements</title><p>We acknowledge the advice of Prof. Omaima Gaber, Dept. of Analytical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria for her review of FTIR spectra. We like to thank as well the staff in the Research Lab Unit, Faculty of Pharmacy, Pharos University in Alexandria for their support in providing instrumental guidance.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abd-Elsalam</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>El-Zahaby</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Al-Mahallawi</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>El-Zahaby</surname>
<given-names>AM.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Formulation and in&#x000a0;vivo assessment of terconazole-loaded polymeric mixed micelles enriched with cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery</article-title>. <source>Drug Deliv</source>
<volume>25</volume>:<fpage>484</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">29411650</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdullahi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Amini-Nik</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jeschke</surname>
<given-names>MG.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Animal models in burn research</article-title>. <source>Cell Mol Life Sci</source>
<volume>71</volume>:<fpage>3241</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">24714880</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abozahra</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Abdelhamid</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Wen</surname>
<given-names>MM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>A nanoparticles based microbiological study on the effect of rosemary and ginger essential oils against <italic>Klebsiella pneumoniae</italic></article-title>. <source>Open Microbiol J</source>
<volume>14</volume>:<fpage>205</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Amanda Velinna Fernandes</surname>
<given-names>LK</given-names></string-name>, <string-name><surname>Raja Pydi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Verma</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Jose</surname>
<given-names>J.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Design, preparation and in&#x000a0;vitro characterizations of fluconazole loaded nanostructured lipid carriers</article-title>. <source>Braz J Pharm Sci</source>
<volume>56</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beloqui</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Solin&#x000ed;s</surname>
<given-names>M&#x000c1;</given-names></string-name>, <string-name><surname>Rodr&#x000ed;guez-Gasc&#x000f3;n</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Nanostructured lipid carriers: promising drug delivery systems for future clinics</article-title>. <source>Nanomedicine</source>
<volume>12</volume>:<fpage>143</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">26410277</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bilia</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Guccione</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Isacchi</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2014</year>). <article-title>Essential oils loaded in nanosystems: a developing strategy for a successful therapeutic approach</article-title>. <source>Evid Based Complement Alternat Med</source>
<volume>2014</volume>:<fpage>651593</fpage>.<pub-id pub-id-type="pmid">24971152</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boughendjioua</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Amoura</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Boughendjioua</surname>
<given-names>Z.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Purity specifications of constituents of cinnamon essential oil by Fourier transformed infrared spectroscopy analysis</article-title>. <source>Indian J Pharm Biol Res</source>
<volume>5</volume>:<fpage>36</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>S-J</given-names></string-name>, <string-name><surname>Sartika</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>G-Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). Animal models of burn wound management. Anim Model Med Biol <fpage>1</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Denisa Ficai</surname>
<given-names>AMG.</given-names></string-name></person-group> (<year>2017</year>). Nanostructured therapeutic systems with bioadhesive and thermoresponsive properties. In: Nanostructures for novel therapy: synthesis, characterization and applications. 1st ed. Maringa, Brazil: Elsevier, <fpage>326</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dumortier</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Grossiord</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Agnely</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Chaumeil</surname>
<given-names>JC.</given-names></string-name></person-group> (<year>2006</year>). <article-title>A review of poloxamer 407 pharmaceutical and pharmacological characteristics</article-title>. <source>Pharm Res</source>
<volume>23</volume>:<fpage>2709</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">17096184</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fakhari</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Corcoran</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schwarz</surname>
<given-names>A.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Thermogelling properties of purified poloxamer 407</article-title>. <source>Heliyon</source>
<volume>3</volume>:<fpage>e00390</fpage>.<pub-id pub-id-type="pmid">28920092</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaba</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Fazil</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride</article-title>. <source>Bull Fac Pharm (Cairo Univ)</source>
<volume>53</volume>:<fpage>147</fpage>&#x02013;<lpage>59</lpage>.</mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garc&#x000ea;s</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Amaral</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Sousa Lobo</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AC.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review</article-title>. <source>Eur J Pharm Sci</source>
<volume>112</volume>:<fpage>159</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">29183800</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ibrahim</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Abdallah</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>El-Megrab</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>El-Nahas</surname>
<given-names>HM.</given-names></string-name></person-group>
<article-title>Transdermal ethosomal gel nanocarriers; a promising strategy for enhancement of anti-hypertensive effect of carvedilol</article-title>. <source>J Liposome Res</source>
<year>2019</year>;<volume>29</volume>:<fpage>215</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">30272506</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jault</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Leclerc</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Jennes</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2018</year>). <article-title>Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by <italic>Pseudomonas aeruginosa</italic> (PhagoBurn): a randomized, controlled, double-blind phase 1/2 trial</article-title>. <source>Lancet Infect Dis</source>
<volume>3099</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jorgensen</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Ferraro</surname>
<given-names>MJ.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Antimicrobial susceptibility testing: a review of general principles and contemporary practices and the rationale for performing</article-title>. <source>Clin Infect Dis</source>
<volume>49</volume>:<fpage>1749</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">19857164</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>YG</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Il Kim</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2015</year>). <article-title>Cinnamon bark oil and its components inhibit biofilm formation and toxin production</article-title>. <source>Int J Food Microbiol</source>
<volume>195</volume>:<fpage>30</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25500277</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Limbago</surname>
<given-names>B.</given-names></string-name></person-group> (<year>2019</year>). Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute.&#x000a0;Galway, Ireland.</mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mukerjee</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pandey</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tripathi</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>SK.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Development, characterization and evaluation of cinnamon oil and usnic acid blended nanoemulsion to attenuate skin carcinogenicity in Swiss Albino mice</article-title>. <source>Biocatal Agric Biotechnol</source>
<volume>20</volume>:<fpage>101227</fpage>.</mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Nanoscale.</collab></person-group> (<year>2018</year>). Nanoscale (<pub-id pub-id-type="doi">10.1080/10717544.2021.1889720</pub-id>), chemical and physical stability of labile APIs in nanodispersions, 6&#x02013;10. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.rsc.org/suppdata/c7/nr/c7nr08488a/c7nr08488a1.pdf">www.rsc.org/suppdata/c7/nr/c7nr08488a/c7nr08488a1.pdf</ext-link> [last accessed 28 Aug 2020].</mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Osman</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Omolo</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Gannimani</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Novel fatty acid-based pH-responsive nanostructured lipid carriers for enhancing antibacterial delivery</article-title>. <source>J Drug Deliv Sci Technol</source>
<volume>53</volume>:<fpage>101125</fpage>.</mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pardeike</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Weber</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Haber</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2011</year>). <article-title>Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application</article-title>. <source>Int J Pharm</source>
<volume>419</volume>:<fpage>329</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">21839157</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raafat</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>El-Zahaby</surname>
<given-names>SA.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Niosomes of active <italic>Fumaria officinalis</italic> phytochemicals: antidiabetic, antineuropathic, anti-inflammatory, and possible mechanisms of action</article-title>. <source>Chinese Med</source>
<volume>15</volume>:<fpage>1</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahim</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Saleha</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2017</year>). <article-title>Bacterial contribution in chronicity of wounds</article-title>. <source>Microb Ecol</source>
<volume>73</volume>:<fpage>710</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">27742997</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Mahant</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nanda</surname>
<given-names>S.</given-names></string-name></person-group> (<year>2018</year>). Nanostructured lipid carriers: revolutionizing skin care and topical therapeutics. In: <person-group person-group-type="editor"><string-name><surname>Grumezescu</surname>
<given-names>AM</given-names></string-name></person-group>, ed. Design of nanostructures for versatile therapeutic applications. William Andrew, Hisar, India: Elsevier Inc., <fpage>97</fpage>&#x02013;<lpage>136</lpage>.</mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sathe</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Saka</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kommineni</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model</article-title>. <source>Drug Dev Ind Pharm</source>
<volume>45</volume>:<fpage>826</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">30764674</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Selcuk</surname>
<given-names>UACT</given-names></string-name>, <string-name><surname>Durgun</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ozalp</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2012</year>). <article-title>Comparison of the antibacterial effect of silver sulfadiazine 1%, mupirocin 2%, Acticoat and octenidine dihydrochloride in a full-thickness rat burn model contaminated with multi drug resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>Burns</source>
<volume>38</volume>:<fpage>1204</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22688192</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seyed Ahmadi</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Farahpour</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Hamishehkar</surname>
<given-names>H.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Topical application of <italic>Cinnamon verum</italic> essential oil accelerates infected wound healing process by increasing tissue antioxidant capacity and keratin biosynthesis</article-title>. <source>Kaohsiung J Med Sci</source>
<volume>35</volume>:<fpage>686</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">31448873</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tavares Pereira</surname>
<given-names>DdS</given-names></string-name>, <string-name><surname>Lima-Ribeiro</surname>
<given-names>MHM</given-names></string-name>, <string-name><surname>de Pontes-Filho</surname>
<given-names>NT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2012</year>). <article-title>Development of animal model for studying deep second-degree thermal burns</article-title>. <source>J Biomed Biotechnol</source>
<volume>2012</volume>:<fpage>460841</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22736951</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teng</surname>
<given-names>JZZ</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability</article-title>. <source>Int J Nanomedicine</source>
<volume>14</volume>:<fpage>119</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">30613141</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>The British Burns Association Research Special Interest Group</collab></person-group>. (<year>2018</year>). The next five years: BBA research priorities: the British Burns Association (BBA). Available at: <ext-link ext-link-type="uri" xlink:href="https://www.britishburnassociation.org/bba-research/">https://www.britishburnassociation.org/bba-research/</ext-link> [last accessed 1 Jun 2020].</mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uprit</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kumar Sahu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pare</surname>
<given-names>A.</given-names></string-name></person-group> (<year>2013</year>). <article-title>Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia</article-title>. <source>Saudi Pharm J</source>
<volume>21</volume>:<fpage>379</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">24227958</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Utchariyakiat</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Surassmo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jaturanpinyo</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2016</year>). <article-title>Efficacy of cinnamon bark oil and cinnamaldehyde on anti-multidrug resistant <italic>Pseudomonas aeruginosa</italic> and the synergistic effects in combination with other antimicrobial agents</article-title>. <source>BMC Complement Altern Med</source>
<volume>16</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26729470</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vasanth</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dubey</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ravi</surname>
<given-names>GS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2020</year>). <article-title>Development and investigation of vitamin C-enriched adapalene-loaded transfersome gel: a collegial approach for the treatment of acne vulgaris</article-title>. <source>AAPS PharmSciTech</source>
<volume>21</volume>:<fpage>61</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">31915948</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>El-Kamel</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Khalil</surname>
<given-names>SA.</given-names></string-name></person-group> (<year>2012</year>). <article-title>Systemic enhancement of papaverine transdermal gel for erectile dysfunction</article-title>. <source>Drug Dev Ind Pharm</source>
<volume>38</volume>:<fpage>912</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22080854</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Farid</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Kassem</surname>
<given-names>AA.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Nano-proniosomes enhancing the transdermal delivery of mefenamic acid</article-title>. <source>J Liposome Res</source>
<volume>24</volume>:<fpage>280</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24779560</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zahir-Jouzdani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Khonsari</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Soleimani</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2019</year>). <article-title>Nanostructured lipid carriers containing rapamycin for prevention of corneal fibroblasts proliferation and haze propagation after burn injuries: in&#x000a0;vitro and in&#x000a0;vivo</article-title>. <source>J Cell Physiol</source>
<volume>234</volume>:<fpage>4702</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30191977</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zainol</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Ming</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Darwis</surname>
<given-names>Y.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Development and characterization of cinnamon leaf oil nanocream for topical application</article-title>. <source>Indian J Pharm Sci</source>
<volume>77</volume>:<fpage>422</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">26664058</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lv</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> (<year>2013</year>). <article-title>Preparation, characterization, and in&#x000a0;vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin</article-title>. <source>Int J Nanomedicine</source>
<volume>8</volume>:<fpage>3227</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">24009420</pub-id></mixed-citation></ref></ref-list></back></article>